Clonazepam in the treatment of psychiatric disorders: an update
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
An updated overview over the past decade is provided with respect to the use of clonazepam in a variety of psychiatric disorders. The efficacy of clonazepam monotherapy for the short-term treatment of panic disorder (PD) was fully established in two large pivotal multicentre studies in the late 1990s in a total of >800 patients. Other studies support a role for clonazepam, in association with selective serotonin reuptake inhibitors (SSRIs), to accelerate treatment response in PD. Although some longitudinal data suggest an ability to maintain improvement without tolerance for up to 3 years, long-term controlled studies of clonazepam in PD are lacking. Studies have shown that clonazepam can also block CO2-induced panic and improve certain aspects of quality of life in PD. Clonazepam has shown some efficacy in social phobia; however, because this evidence is based on few studies, further studies are warranted before definitive conclusions can be drawn. Finally, evidence for the use of clonazepam in acute mania and as augmentation therapy with SSRIs to accelerate response in depression is examined. The long half-life and higher potency of clonazepam may allow easier discontinuation with fewer withdrawal symptoms compared to other benzodiazepines and studies using a slow clonazepam taper appear promising.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404 · cited 1×
“The 78% response rate with clonazepam contrasts with reported rates as low as 38% with alprazolam (Gelernter et al., 1991).”
BackgroundPecknold, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290043006 · Cited by 204
Otto, M. W., Pollack, M. H., Gould, R. A., Worthington, J. J., McArdle, E. T., Rosenbaum, J. F., & Heimberg, R. G. (2000) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(00)00027-x · Cited by 175 · cited 1×
“In a recent 12-week study, the efficacy of clonazepam (titrated to maximum of 4 mg/day) was compared with cognitive behavioural group therapy (CBGT) in 45 social phobia patients (Otto et al., 2000).”
MethodClomipramine, Clonazepam, and Clonidine Treatment of Obsessive-Compulsive Disorder
HEWLETT, W. A., VINOGRADOV, S., & AGRAS, W. S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199212000-00008 · Cited by 129 · cited 2×
“study, clonazepam was shown to be effective in reducing OCD symptoms compared to control medication (diphenhydramine) (Hewlett et al., 1992).”
BackgroundA double-blind, placebo-controlled trial of clonazepam in obsessive–compulsive disorder
Hollander, E., Kaplan, A., & Stahl, S. M. (2003) · The World Journal of Biological Psychiatry · doi:10.3109/15622970309167908 · Cited by 97 · cited 3×
“However, recent data, from a 10-week placebo-controlled trial in 27 patients suggest that clonazepam (intent-to-treat mean maximum dose 3.2 mg/day) is not effective as monotherapy in OCD, with response rates to clonazepam no different to those with placebo (Hollander et al., 2003).”
BackgroundInfluentialA 2-Year Follow-up of Social Phobia: Status After a Brief Medication Trial
SUTHERLAND, S. M., TUPLER, L. A., COLKET, J. T., & DAVIDSON, J. R. T. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199612000-00003 · Cited by 35
Cited by
Benzodiazepine pharmacology and central nervous system-mediated effects.
(2013) · Europe PMC (PubMed Central) · Cited by 650
Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
“In comparison to patients with generalized anxiety, PD patients are more likely to be unsuccessful in discontinuing benzodiazepines [62].”
BackgroundEmerging drugs for panic disorder
Perna, G., Guerriero, G., & Caldirola, D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.628313 · Cited by 23
“4 Benzodiazepines The high-potency BDZs, such as clonazepam and alprazolam, are an effective medication in the treatment of PD [36,37].”
BackgroundSelf-citation
Metadata
- Authors
- Nardi, A. E., & Perna, G.
- Venue
- International Clinical Psychopharmacology
- Published
- 2006-05
- Volume
- 21
- Issue
- 3
- Pages
- 131-142
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2020761505
- Cited by
- 52
- References
- 6
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clonazepam in the treatment of psychiatric disorders: an update. https://app.cochat.ai/papers/10.1097/01.yic.0000194379.65460.a6
- The paper
- Nardi, A. E., & Perna, G. (2006). Clonazepam in the treatment of psychiatric disorders: an update. International Clinical Psychopharmacology. https://doi.org/10.1097/01.yic.0000194379.65460.a6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.